A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizoaffective disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Pharmaceuticals; Janssen-Cilag
  • Most Recent Events

    • 17 Jun 2016 Results published in the Journal of Clinical Psychopharmacology
    • 20 Oct 2014 Results presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
    • 06 May 2014 Primary endpoint 'Time-to-relapse' has been met, according to a Janssen Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top